Targeting Nurr1 & Proteasome Activation in Parkinson’s Disease: Advancing MT101 for Phase II Initiation
2:30 pm - Thursday 10th December 2026
- Reviewing pipeline development history of innovative botanical drug candidate, MT101, for Parkinson’s Disease
- Demonstrating how Nurr1 activation induces dopaminergic gene expression and proteasome activation, subsequently inhibiting alpha-synuclein aggregation
- Showcasing Phase I safety and tolerability data in elderly populations and detailing future directions for Phase IIa initiation in US
